Sphingosine kinase 2 inhibitors for modulating the production of sphingosine-1-phosphate (S1P)—a potential treatment of cancer, sickle cell disease, atherosclerosis, asthma, diabetes, and fibrosis. This evidence concerns the gene SPHK2 and atherosclerosis.